Key result
Prolonged intravenous amiodarone can induce Torsades de pointes and should be avoided as first-line therapy in patients without heart disease, requiring careful QT interval monitoring.
Why the study?
Does prolonged intravenous amiodarone therapy induce Torsades de pointes in patients with atrial fibrillation?
Does prolonged intravenous amiodarone therapy induce Torsades de pointes in patients with atrial fibrillation?
Prolonged intravenous amiodarone can induce Torsades de pointes, highlighting the need for careful QT interval monitoring and avoiding it as first-line therapy in patients without structural heart disease.
May support QT monitoring with prolonged IV amiodarone; hypothesis-generating for torsades risk in AF without structural heart disease.
Amiodarone can induce TdP; therefore, it should be avoided as a first choice for therapy in patients without heart disease. Careful QT interval monitoring, especially during intravenous use, can prevent development of this life-threatening arrhythmia.
No takes yet. Share an insight, caveat, or question.
Nordkin et al. (2020) studied this question. Prolonged intravenous amiodarone can induce Torsades de pointes and should be avoided as first-line therapy in patients without heart disease, requiring careful QT interval monitoring.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: